[EpochTimesNovember092021](Epoch Times reporter Li Bing comprehensive report) As China’s current round of the epidemic spread to 20 provinces, the share price of A-share vaccine leader Cansino plummeted over 10% on November 8. The high market value has evaporated by nearly 140 billion yuan (RMB, the same below). On that day, the total market value of the A-share vaccine sector evaporated by more than 34.5 billion yuan.
On the 8th, Kangsino, which was listed on the Science and Technology Innovation Board, fell 9.91%, a new low since its listing; Watson Biotech plunged more than 6% on the market, and its stock price has been cut from the high level of the year; In addition, Fosun Pharma, Wantai Biotech, and Zhifei Biological and unnamed medicines have fallen one after another.
As of the close, the vaccine index closed down by nearly 3%, and the total market value of Wind’s vaccine sector fell back to 931.9 billion yuan, and the total market value lost more than 34.5 billion yuan in a single day.
The Hong Kong stocks’ vaccine and biological sector also suffered a severe setback on the 8th. According to the “Securities Times” report, as of the close of trading, CanSino Biotech has fallen sharply by more than 17%; Zai Lab-B has fallen by more than 17%, and WuXi Biologics has fallen by more than 8%.
Cansino was once known as the “first vaccine stock”. Its stock price reached a historical high of 798 yuan per share in June this year, and its total market value once reached 197.1 billion yuan. Since then, Cansino’s stock price has gone down all the way. According to data from Oriental Fortune.com, as of November 8, Cansino’s stock price was 239 yuan, with a total market capitalization of 59 billion yuan, and nearly 140 billion yuan in market value in five months.
Mainland media believe that the seesaw effect of the vaccine anti-epidemic sector of A shares today is mainly due to the significant progress of Pfizer’s new crown drugs, which has given the market expectations for epidemic control.
On November 5, the American pharmaceutical company Pfizer (Pfizer) announced on its official website that compared with placebo, its oral drug Paxlovid for new crowns can be taken within three days after the symptoms of patients infected with new crowns. The probability of being hospitalized or dying in adult patients was reduced by 89%.
Lu Media said that Pfizer’s new crown drug is not good news for the A-share vaccine anti-epidemic sector, and it directly shakes investors’ confidence in Chinese vaccine companies.
However, the epidemic in mainland China has recently made a comeback. The Joint Prevention and Control Mechanism of the State Council of the Communist Party of China held a press conference on November 6. Wu Liangyou, deputy director of the CDC of the Health Commission, said that since October 17, the epidemic has spread to 20 provinces and 44 cities.
The official mentioned that the epidemic situation in Heilongjiang, Hebei, Henan, Jiangxi, Sichuan, Chongqing, Dalian, Liaoning and other places is still developing. On the whole, the epidemic presents the characteristics of multiple transmission chains, fast transmission speed, and wide transmission range. The prevention and control situation is still severe and complex.
In addition, in terms of vaccine and epidemic prevention, according to the Chinese Communist Party’s Health Commission, as of November 4 this year, 31 provinces and the Xinjiang Production and Construction Corps have reported a total of more than 2.3 billion doses of vaccination. In addition, the authorities are carrying out the promotion of the third booster vaccination, and the Cansino vaccine has been selected for the booster vaccination category.
Editor in charge: Sun Yun#
.